Spots Global Cancer Trial Database for Nadolol Versus Propranolol in Children With Infantile Hemangiomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nadolol Versus Propranolol in Children With Infantile Hemangiomas
Official Title: Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial
Study ID: NCT02505971
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy and safety of oral propranolol versus nadolol in patients with Infantile Hemangiomas (IH) in a randomized, controlled, double-blinded study.
Detailed Description: The study objective is to compare the efficacy and safety of oral propranolol in comparison with oral nadolol in patients with IH. Patients will be randomly assigned to either propranolol or dose equivalent nadolol. The duration of the study will be 24 weeks, however, patient will be monitored for up to 1 year post study enrolment. Both efficacy and safety will be closely monitored and captured.
Keywords
Eligibility
Minimum Age: 1 Month
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Locations
The Hospital for Sick Children, Toronto, Ontario, Canada
Contact Details
Name: Elena Pope, MD, MSc
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
